Latest Breaking News On - Taysha gene therapies - Page 14 : comparemela.com

DelveInsight Business Research, LLP: Navigating the Complex Market Landscape of Rare Genetic Disorders: A Deep Dive into Hereditary Angioedema, Wilson Disease, Menkes Disease, and Alpha-1 Antitrypsin Deficiency (AATD)

DelveInsight Business Research, LLP: Navigating the Complex Market Landscape of Rare Genetic Disorders: A Deep Dive into Hereditary Angioedema, Wilson Disease, Menkes Disease, and Alpha-1 Antitrypsin Deficiency (AATD)
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomAvanti biosciencesShruti thakurReveragen biopharmaDaiichi sankyoMereo biopharmaVyant bioDaelis farmaAnnovis bioZynerba pharmaceuticalsDicerna pharmaceuticalsArrow head pharmaceuticalsRare disease consulting servicesAstria therapeutics incNeuronascent inc

Pliant Therapeutics Appoints S Mishima Gerhart as Chief Regulatory Officer

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the appointment of Ms. S. Mishima Gerhart as Chief Regulatory Officer. Ms. Gerhart will lead the Company’s regulatory and quality strategies and activities. “Mishima brings a dynamic set of drug development experiences including the d

United statesBernard coulieS mishima gerhartChristopher keenanCorporate communicationsDrug administrationEuropean medicines agencyPliant therapeutics incHead of regulatory affairsRegulatory affairsCompany onKutztown universityTemple universityReata pharmaceuticalsChief regulatoryChief executive officer

Taysha Doses Second Patient With Rett Syndrome With TSHA-102, per IDMC Recommendation

Both the second and first patients dosed in the study received the lower of the 2 doses of the gene therapy that Taysha Gene Therapies is evaluating in the phase 1/2 REVEAL trial.

Women healthDigital healthRett syndromeTsha 102Idmcs recommendationTaysha gene therapies

Taysha Gene Therapies, Inc (NASDAQ:TSHA) Receives $7 91 Consensus PT from Analysts

Taysha Gene Therapies, Inc (NASDAQ:TSHA) Receives $7 91 Consensus PT from Analysts
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Paulb manningKamran alamSecurities exchange commissionNeedham companyNantahala capital managementQuantum private wealthCantor fitzgeraldTaysha gene therapies incSwiss national bankCommonwealth equity servicesCanaccord genuity groupVirtu financialTaysha gene therapiesGet free reportMarketbeat ratingsGenuity group

Short Interest in Taysha Gene Therapies, Inc (NASDAQ:TSHA) Increases By 34 9%

Taysha Gene Therapies, Inc. (NASDAQ:TSHA – Get Free Report) was the target of a large growth in short interest in September. As of September 15th, there was short interest totalling 9,930,000 shares, a growth of 34.9% from the August 31st total of 7,360,000 shares. Based on an average daily volume of 4,830,000 shares, the days-to-cover […]

Robertw bairdKamran alamCapital managementDynamic advisor solutionsCommonwealth equity servicesNeedham companyVirtu financialTaysha gene therapies incMaven securitiesCanaccord genuity groupTaysha gene therapiesGet free reportGene therapiesTaysha geneAdvisor solutionsEquity services